	Jacobs Engineering Group was awarded a contract to expand the Novartis Pharma S.A.S. Biotechnology Center in Huningue, France, the company announced on Aug. 11, 2016. Under the terms of the agreement, Jacobs is providing engineering, procurement, and construction management services to increase the site’s production capacity by 70% and create a second line of purification that allows for multiple drugs to be manufactured simultaneously.

	Already one of the world’s largest production facilities for monoclonal antibodies from mammalian cells, the expansion project adds cell culture bioreactors to the site. The $100 million expansion project is scheduled to be completed in four years. Jacobs’ services are being led from its operations in Milan, Italy.

Bio/Pharma News

Biologic Drugs

Dosage Forms

PharmTech Europe News

PharmTech News

Jacobs Engineering will provide engineering and construction services to expand the Novartis site in Huningue, France.